"No rare cancer clinical trial should fail because it cannot recruit patients. We have the patients, we have the trials, and we can work together to improve access, adherence, and the rapid translation of trial data into practice," said RCA CEO Christine Cockburn.
National talks aim to address rare cancer clinical trial inequities
September 22, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
CSL absorbs loss in reset year as investors back its plasma-led recovery
August 18, 2026 - - Latest News -
Vinnies named inaugural partner of Pharmacy Guild Foundation
August 18, 2026 - - Latest News -
Opportunity #2 - AI can democratise HTA and the negotiations must not squander it
August 18, 2026 - - Latest News -
Opportunity #1 - biosimilar policy failure has become impossible to ignore
August 18, 2026 - - Latest News -
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
August 17, 2026 - - Australian Biotech -
Dimerix takes control of US development pathway for new kidney injury treatment
August 17, 2026 - - Australian Biotech -
OncoSil secures FDA approval for targeted bile duct cancer device
August 17, 2026 - - Latest News

